Alpha-1 Foundation DNA and Tissue Bank
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00884455|
Recruitment Status : Enrolling by invitation
First Posted : April 20, 2009
Last Update Posted : June 6, 2019
|Condition or disease|
|Alpha 1 Antitrypsin Deficiency|
Subject participation includes completion of informed consent, medical questionnaire, and email authorization. Subjects may provide a blood sample for alpha-1 antitrypsin genotype, phenotype and level. Lung and liver tissue may also be provided if available. Subjects may be contacted no more often than annually for updated information.
This project has a certificate of confidentiality from NIH.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Alpha-1 Foundation DNA and Tissue Bank|
|Study Start Date :||December 2002|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
- Data and tissue samples [ Time Frame: The total number of tissue samples received and used for research are tracked annually. ]At the end of 15 years the tissue and data sample usage will be analyzed to determine continuation of the project. Each year the investigator provides a summary to the Alpha-1 Foundation.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00884455
|United States, Florida|
|University of Florida|
|Gainesville, Florida, United States, 32610|
|Principal Investigator:||Mark L Brantly, MD||University of Florida|